Michael MacDougall – EMD Serono

The business of saving lives

Michael MacDougall – EMD Serono

There are nearly one million people living with multiple sclerosis in the U.S. That’s about the same as the number of people living in Austin, Texas, the 11th largest city in the country.

It is an unpredictable disease that strikes women two or three times more often than men. The progress, severity and symptoms affect each person differently, making it difficult to diagnose and treat.

Cancer is also unpredictable, has no cure and impacts millions and millions of people every year. Researchers at EMD Serono have been hard at work developing immunotherapies to fight cancers like bladder, lung and skin, in addition to the products that fight MS.

The focus on difficult-to-treat diseases maximizes the importance of potential treatments, says Michael MacDougall, the senior vice president and general counsel for EMD Serono, the Massachusetts-based biopharmaceutical business of Merck KGaA in Darmstadt, Germany, which has been developing drugs to fight these diseases for many years.

“We all know someone impacted by multiple sclerosis or cancer and this motivates our team to do everything we can to help bring new treatments to patients,” MacDougall says.

Helping people battle hard-to-treat diseases

More than finding treatments, MacDougall says EMD Serono has an ongoing commitment to improve the entire experience for people fighting MS and cancer.

In recent years, he has navigated the legal challenges of launching products while “staying laser-focused on” supporting EMD Serono’s existing therapies.

“However, effective legal teams need to find a way to manage the increased workload and complexity that comes with a product launch, while maintaining the same level of resource and attention on current products that often continue to bring in significant revenue,” MacDougall says.

This, he notes, requires discipline so the legal team is spending its time efficiently and effectively to support the business.

No matter the challenge, MacDougall says he and his team have faced them head-on, leaning on decades of combined experience to advance the treatment of illnesses like MS and cancer, and the more than 20 projects currently in EMD Serono’s pipeline.

“We have an extremely talented and experienced legal team, and as long as there are people in this world that need help with difficult-to-treat diseases, we’ll keep working hard to help them,” he states.

Biopharma never stops

During MacDougall’s time at EMD Serono, there was a period where the company didn’t launch any new products, which can occur as biopharma companies go through the arduous process of discovering, developing and getting new drugs approved. Despite that, employees were working as hard as ever. Legal work has consistently supported the company’s medical, commercial, regulatory, R&D, market access and litigation matters, among other work. And in recent years, it’s picked up.

“We have a legacy portfolio that continues to do very well, and there’s a lot of work supporting these existing commercial brands,” he says. “Since 2017, we’ve launched a new immuno-oncology therapy now approved in multiple indications, as well as a new MS therapy. We’re launching a new product or indication about every year.”

Michael MacDougall – EMD Serono

The fast pace and high stakes of the biopharmaceutical industry are a couple of the reasons why MacDougall was drawn to it. The six months before a product launches and the six months after are pretty intense, he says, and immediately after launch is the period of time where a company can set the trajectory for the product’s success.

“We really get one shot to launch strongly, so there’s a lot of focus, a lot of activity and a lot of creative thinking,” MacDougall says. “It’s where the legal team can really contribute to the company’s success by demonstrating a practical, collaborative and problem-solving mindset.”

In addition to launching products and the legal work that comes with it, there are always new projects, strategies and initiatives that need legal support throughout the company. Training new employees, handling legal and compliance issues that surface, and new ways to mitigate risk need to be evaluated and implemented.

“In this industry, there’s always a core set of work that exists, and that work will increase the more products the company launches. And if you have an existing portfolio, particularly in competitive therapeutic areas, that work remains constant,” MacDougall says.

From tech to biopharma

After graduating with a degree in finance from Boston College, he went on to Boston College Law School, completing his juris doctor in 1996. His father was a corporate lawyer, so becoming an attorney felt natural. Working as an in-house attorney was the goal, but he knew he had to pay his dues and gain invaluable experience at a law firm first.

He got his first job as an associate at the law firm of Sullivan & Worcester in Boston and stayed there for four years before moving in-house to work for two different technology companies for about five years.

In 2007, MacDougall made the jump to EMD Serono, and for the first six years of his career, he was an associate general counsel of the commercial business. In that role, he supported the market access team as well as all other commercial operations and functions such as distribution, business excellence, finance, government pricing and government affairs. He then moved with his family to Darmstadt, Germany—the global headquarters of Merck KGaA, EMD Serono’s parent company—where he became the associate general counsel, head of legal for global business franchises.

Michael MacDougall – EMD Serono

There, he led and managed an international team that provided legal support in oncology, neurology, immunology, endocrinology, general medicine and fertility.

“One of the reasons I like this company is the opportunity to interact with legal and business colleagues from all over the world as the company has a presence in 66 countries,” MacDougall notes.

He returned to the U.S. and became EMD Serono’s vice president and general counsel in November 2015—he was named senior vice president and general counsel in January 2019.

MacDougall says it’s been an exciting career so far and there’s still plenty of work to do at EMD Serono. Being part of a company that has such an impact on people’s lives—and having that be a driving focus—has been fulfilling.

“It really is a unique industry where you can be excited about what your company is doing and knowing that you are all working towards a goal of helping people,” MacDougall adds.

Published on: November 3, 2020



Showcase your feature on your website with a custom “As Featured in Vanguard” badge that links directly to your article!

Copy and paste this script into your page coding (ideally right before the closing tag) where you want to display our review banner.


As promised in advance, my feature in Vanguard has increased my visibility within the profession and prompted more than a few people I have not communicated with recently to reconnect. One of the Italian law firms I have used in the past is now in the process of interviewing me for an article on their website and tweeting out the feature story. Activity and the number of people connecting with me on LinkedIn has soared, which is great. The Vanguard writers and editorial staff were great to work with—highly professional and made the effort to make the experience both fun and rewarding (they were also respectful of the time pressures and demands all lawyers face). I was very pleased with the experience and the final outcome. Needless to say, I have been very pleased. All in all working with Vanguard has been a very positive experience which generated good publicity for both Shawcor and myself. My sincere thanks.
– Tim Hutzul, General Counsel, ShawCor Ltd.
I was honored to be the subject of an article. I enjoy reading Vanguard articles and seeing how other attorneys got to their positions and see their jobs. It's also interesting to see how different law firms partner with the subjects of the articles.
– Henry Marquard, in-house counsel, Stanley Consultants Inc.
The piece highlighting my company, Bob Baker Enterprises, Inc., came out fabulous. Our company is in the new and used car sales and service industry. Everyone was great to work with and extremely professional. They produced a high-quality product and have provided expert assistance and guidance post-production of the article.
– Wade Poulson, General Counsel, Bob Baker Enterprises Inc.
It was a great honor to be featured in Vanguard Law. Working with every member of the team, from the initial interview with Erin Clark, through production with Victor Martins, writing the article with Taryn Plumb and creating the final content with Dave Gushee, was a true pleasure. Everyone was very professional, enthusiastic and supportive, and their creative approach and positive attitude clearly came through in the final product.
– Kevin C. Rakowski, Senior Vice President, Deputy General Counsel, Compliance with Radian Group Inc.


Spring IV 2024



  • * We’ll never share your email or info with anyone.
  • This field is for validation purposes and should be left unchanged.